‘Pomalyst’ applied for insurance benefit while 48 products removed

From January next year, ‘Pomalyst Cap,’ a multiple myeloma treatment, will be applied for the health insurance benefit under the risk sharing(return type) application, and ‘Sunpla,’ a Korean new drug, will be removed from the benefit.

The Ministry of Health and Welfare(MOHW) announced a partial revision of the ‘Insured Drug List and Upper Limit Price Table’ containing the contents mentioned ab...